October 12, 2018
Keio University Institute for Advanced Biosciences
Shonai Regional Industry Promotion Center
In a joint research project between the Keio University Institute for Advanced Biosciences (Tsuruoka, Yamagata Prefecture; Director Masaru Tomita), the National Cancer Center (Chuo-ku, Tokyo; President Hitoshi Nakagama), and the Shonai Regional Industry Promotion Center (Tsuruoka, Yamagata Prefecture; President Mitsugi Kobayashi), Yuzo Sato, a graduate student at Keio University (Doctoral Programs, Graduate School of Media and Governance) and an employee of the Shonai Regional Industry Promotion Center, in collaboration with Team Leader Hideki Makinojima and others at the National Cancer Center Tsuruoka Collaborative Research Base, has discovered differences in sensitivity to antimetabolites among multiple malignant pleural mesothelioma cell lines. Furthermore, the study clarified the changes in metabolites resulting from the treatment with these drugs and their metabolites, demonstrating the importance of capturing changes not only in protein and gene expression but also in metabolites. This announcement marks the first paper from the joint research of the three institutions, and it is expected to lead to the search for useful metabolic biomarkers for the treatment of malignant pleural mesothelioma and the elucidation of drug resistance mechanisms. The findings of this research were published in the online edition of the Swiss pharmacology journal "Frontiers in Pharmacology" on October 12, 2018, at 6:00 a.m. (1:00 p.m. JST).
For the full press release, please see below.